-
$KPTI: Research Costs Blew the Quarter; The Filing Still Stands earnings_post · 2026-08-13-KPTI · Aug 13, 2:58 PM ETThe miss is a development bill, not a franchise break. Cash runway and the filing clock are what the tape should price, not the EPS print.
-
$YXT: H1 2026 Loss + Dilutive Direct Offering earnings_post · 2026-08-13-YXT · Aug 13, 3:41 PM ETYXT.com reports $0.01 EPS loss for H1 2026; simultaneous $1.05M registered direct offering signals capital constraints.
-
$FFAI: Q2 Earnings Preview — $61.19 EPS Loss & Robotics Margin Test earnings_pre · 2026-08-13-FFAI · Aug 14, 5:29 AM ETConsensus expects a $61.19 per-share loss. The market is pricing in a pivot to EAI Robotics, but Nasdaq compliance remains the immediate threat.
-
$CLRO: Jun '26 Earnings Setup — Cortigent Merger & Guidance earnings_pre · 2026-08-13-CLRO · Aug 13, 3:45 PM ETClearOne reports Q1 Jun '26 results; market eyes Cortigent unit merger impact and forward revenue visibility.
-
$YXT: H1 2026 Results Show $0.01 Loss; Capital Raise Dilution Weighs earnings_pre · 2026-08-13-YXT · Aug 13, 3:39 PM ETYXT.com reports first-half 2026 results with a $0.01 EPS loss, following a $1.05M direct offering that adds dilution pressure to the micro-cap stock.
-
$KPTI: Q2 Loss Widens on Cash Burn; SNDA Timeline Key earnings_pre · 2026-08-13-KPTI · Aug 13, 2:57 PM ET
Karyopharm reports a deeper-than-expected Q2 loss, signaling accelerated cash consumption ahead of the critical myelofibrosis sNDA submission.